Cat. No. | Product name | CAS No. |
DC11707 |
MDVN-1003
A first-in-class, selective, orally bioavailable, dual inhibitor of BTK and PI3Kδ kinases with IC50 of 32.3 nM and 16.9 nM, respectively. |
2058116-54-2 |
DC11804 |
IQS-019
A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
1630804-24-8 |
DC11805 |
IQS-019 mesylate
A novel, potent inhibitor of most upstream tyrosine kinases in BCR signaling pathway, inhibits BCR kinases Lyn, Syk and Btk with IC50 of 0.15 uM, 1.6 uM and 2.1 uM, respectively. |
1630804-27-1 |
DC9660 |
Acalabrutinib(ACP196)
Featured
Acalabrutinib (ACP-196) is a second-generation, selective, irreversible inhibitor of BTK. |
1420477-60-6 |
DC10975 |
ARQ-531
Featured
ARQ-531 is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, |
2095393-15-8 |
DC5014 |
AVL-292
Featured
AVL-292 is a covalent, highly selective, orally active small molecule inhibitor of Btk currently being evaluated in a Phase 1b clinical trial in relapsed. |
1202757-89-8 |
DC10335 |
BGB-3111
BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. |
1633350-06-7 |
DC11819 |
BMS-986142
Featured
BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
1643368-58-4 |
DC12030 |
BMS-986195
Featured
BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
1912445-55-6 |
DC7380 |
CGI-1746
Featured
CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. |
910232-84-7 |
DC10380 |
Evobrutinib
Featured
Evobrutinib is an inhibitor of Bruton's tyrosin kinase (Btk) inhibitor extracted from patent US20140162983 example 0174. |
1415823-73-2 |
DC7937 |
LFM-A13
Featured
FM-A13 is a selective inhibitor of Bruton’s tyrosine kinase (BTK) – IC₅₀’s = 2.5 µM (recombinant BTK) and 17.2 µM (human BTK). |
244240-24-2 |
DC11776 |
G-744
G-744 is a highly potent, selective inhibitor of BTK with biochemical Ki of 1.28 nM. |
1346669-54-2 |
DC9942 |
GDC-0853(RG7845)
Featured
GDC-0853 is orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. |
1434048-34-6 |
DC10043 |
ONO4059 hydrochloride
Featured
ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
1439901-97-9 |
DC8358 |
ONO-4059(Tirabrutinib)
Featured
ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase. |
1351636-18-4 |
DC10757 |
PCI-29732
Featured
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay. |
330786-25-9 |
DC1106 |
PCI-32765 (Ibrutinib)
Featured
PCI-32765 (Ibrutinib) is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM. |
936563-96-1 |
DC11914 |
Poseltinib
Featured
Poseltinib (HM-71224, LY-3337641) is a potent and selective, covalent inhibitor of Btk with IC50 of 1.95 nM. |
1353552-97-2 |
DC5146 |
RN486
Featured
RN-486 is a Bruton's tyrosine kinase (Btk) inhibitor. |
1242156-23-5 |
DC10044 |
ONO4059 analog
Featured
The product is the analog of ONO-4059, ONO-4059 is a highly potent and selective Btk inhibitor with an IC50 in the sub-nM range. |
1351635-67-0 |
DC11471 |
BGB-3111(Zanubrutinib)
Featured
Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor. |
1691249-45-2 |